172 related articles for article (PubMed ID: 31841792)
1. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma.
Latenstein AEJ; van der Geest LGM; Bonsing BA; Groot Koerkamp B; Haj Mohammad N; de Hingh IHJT; de Meijer VE; Molenaar IQ; van Santvoort HC; van Tienhoven G; Verheij J; Vissers PAJ; de Vos-Geelen J; Busch OR; van Eijck CHJ; van Laarhoven HWM; Besselink MG; Wilmink JW;
Eur J Cancer; 2020 Jan; 125():83-93. PubMed ID: 31841792
[TBL] [Abstract][Full Text] [Related]
2. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
3. Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012.
Hester CA; Dogeas E; Augustine MM; Mansour JC; Polanco PM; Porembka MR; Wang SC; Zeh HJ; Yopp AC
J Surg Oncol; 2019 Mar; 119(3):303-317. PubMed ID: 30561818
[TBL] [Abstract][Full Text] [Related]
4. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
5. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
[TBL] [Abstract][Full Text] [Related]
6. Patients with resected, histologically re-confirmed pancreatic ductal adenocarcinoma (PDAC) can achieve long-term survival despite T3 tumour or nodal involvement. The Finnish Register Study 2000-2013.
Ahola R; Siiki A; Vasama K; Vornanen M; Sand J; Laukkarinen J
Pancreatology; 2017; 17(5):822-826. PubMed ID: 28789903
[TBL] [Abstract][Full Text] [Related]
7. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis.
van Erning FN; Mackay TM; van der Geest LGM; Groot Koerkamp B; van Laarhoven HWM; Bonsing BA; Wilmink JW; van Santvoort HC; de Vos-Geelen J; van Eijck CHJ; Busch OR; Lemmens VE; Besselink MG;
Acta Oncol; 2018 Dec; 57(12):1655-1662. PubMed ID: 30264642
[TBL] [Abstract][Full Text] [Related]
8. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
9. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis.
Blackford AL; Canto MI; Klein AP; Hruban RH; Goggins M
J Natl Cancer Inst; 2020 Nov; 112(11):1162-1169. PubMed ID: 31958122
[TBL] [Abstract][Full Text] [Related]
10. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
13. Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma.
Kim Y; Kim SC; Song KB; Kim J; Kang DR; Lee JH; Park KM; Lee YJ
HPB (Oxford); 2016 Apr; 18(4):325-31. PubMed ID: 27037201
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Adenocarcinoma Causing Necrotizing Pancreatitis: Not as Rare as You Think?
Lewellen KA; Maatman TK; Heimberger MA; Ceppa EP; House MG; Nakeeb A; Schmidt CM; Zyromski NJ
J Surg Res; 2020 Jun; 250():53-58. PubMed ID: 32018143
[TBL] [Abstract][Full Text] [Related]
16. Age and prognosis in patients with pancreatic cancer: a population-based study.
van Dongen JC; van der Geest LGM; de Meijer VE; van Santvoort HC; de Vos-Geelen J; Besselink MG; Groot Koerkamp B; Wilmink JW; van Eijck CHJ;
Acta Oncol; 2022 Mar; 61(3):286-293. PubMed ID: 34935577
[TBL] [Abstract][Full Text] [Related]
17. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of second primary pancreatic cancer.
Jo JH; Cho IR; Jung JH; Lee HS; Chung MJ; Bang S; Park SW; Chung JB; Song SY; Park JY
PLoS One; 2017; 12(6):e0179784. PubMed ID: 28650984
[TBL] [Abstract][Full Text] [Related]
19. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC).
Duconseil P; Périnel J; Autret A; Adham M; Sauvanet A; Chiche L; Mabrut JY; Tuech JJ; Mariette C; Régenet N; Fabre JM; Bachellier P; Delpéro JR; Paye F; Turrini O
Eur J Surg Oncol; 2017 Sep; 43(9):1704-1710. PubMed ID: 28687431
[TBL] [Abstract][Full Text] [Related]
20. Neo-adjuvant therapy for pancreatic cancer: hope for the future.
Borazanci E; Sckolnik S; Amini A
Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):579-589. PubMed ID: 30979348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
